Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

180
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

143
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
143
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

243
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
243
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

332
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
332
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

239
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
239
Pneumonia IV: Management01:28

Pneumonia IV: Management

329
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
329

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modified string test to improve and confirm by molecular characterization for bacterial identification.

Access microbiology·2026
Same author

Outcomes of pediatric inguinal hernias at a tertiary hospital in South-Western Uganda.

Hernia : the journal of hernias and abdominal wall surgery·2026
Same author

Prevalence, associated factors and outcomes of maternity blues among postpartum mothers: a multi-facility prospective cohort in rural Southwestern Uganda.

Archives of women's mental health·2026
Same author

Trends in all-cause mortality after cancer diagnosis among people with and without HIV in Botswana, 1990-2021.

Cancer causes & control : CCC·2026
Same author

Spatiotemporal Patterns of AIDS-Defining and Non-AIDS-Defining Cancers before and after Antiretroviral Therapy Rollout in Botswana, 1990 to 2021.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol.

PloS one·2026
Same journal

Public Health Response to Clade Ib Mpox with Multiple Exposures in Congregate Living Settings - New Hampshire, February 2025.

NEJM evidence·2026
Same journal

Berberine-Ursodeoxycholate - Bringing Traditional Chinese Medicine to Our World.

NEJM evidence·2026
Same journal

Outbreak of Legionnaires' Disease Associated with Cooling Tower Systems in Central Harlem.

NEJM evidence·2026
Same journal

Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency.

NEJM evidence·2026
Same journal

A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making.

NEJM evidence·2026
Same journal

Evidence for Evidence-Based Medicine - A Call for Some Theory and a New Problem.

NEJM evidence·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis.

Amina Jindani1, Daniel Atwine2,3, Daniel Grint4

  • 1Institute for Infection and Immunity, St. George's, University of London, London.

NEJM Evidence
|February 6, 2024
PubMed
Summary
This summary is machine-generated.

Shorter tuberculosis treatment regimens using high-dose rifampicin were evaluated. Four-month regimens did not prove noninferior to the standard 6-month treatment for pulmonary tuberculosis, despite acceptable safety profiles.

More Related Videos

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

80.7K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K

Related Experiment Videos

Last Updated: Jul 4, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

80.7K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Shorter, effective tuberculosis (TB) treatment regimens are needed.
  • High-dose rifampicin shows potential for faster lung sterilization and enabling shorter TB treatment durations.

Purpose of the Study:

  • To evaluate the noninferiority of 4-month high-dose rifampicin regimens compared to a standard 6-month regimen for pulmonary tuberculosis.
  • To assess the safety and efficacy of two high-dose rifampicin regimens (1200 mg/d and 1800 mg/d) against a standard regimen.

Main Methods:

  • Randomized controlled trial involving adults with rifampicin-susceptible pulmonary tuberculosis.
  • Comparison of a 6-month control regimen with two 4-month high-dose rifampicin regimens (SR1: 1200 mg/d, SR2: 1800 mg/d).
  • Primary endpoint: composite of treatment failure and relapse in sputum smear-positive patients; noninferiority margin set at 8 percentage points.

Main Results:

  • Noninferiority was not demonstrated for the 4-month high-dose rifampicin regimens.
  • Favorable response rates were 93% (control), 90% (SR1), and 87% (SR2).
  • Grade 3 or 4 adverse events were comparable across groups (4.0% control, 4.5% SR1, 4.4% SR2).

Conclusions:

  • Four-month high-dose rifampicin regimens did not meet noninferiority criteria for pulmonary tuberculosis treatment.
  • These regimens exhibited acceptable safety profiles without dose-limiting toxicities.
  • The standard 6-month regimen remains the benchmark for effective pulmonary tuberculosis treatment.